| Texto completo | |
| Autor(es): |
Paes, Lisvane Silva
[1]
;
Mantilla, Brian Suarez
[1]
;
Barison, Maria Julia
[1]
;
Wrenger, Carsten
[1]
;
Silber, Ariel Mariano
[1]
Número total de Autores: 5
|
| Afiliação do(s) autor(es): | [1] Univ Sao Paulo, Inst Ciencias Biomed, Dept Parasitol, BR-05508 Sao Paulo - Brazil
Número total de Afiliações: 1
|
| Tipo de documento: | Artigo de Revisão |
| Fonte: | CURRENT PHARMACEUTICAL DESIGN; v. 17, n. 20, p. 2074-2099, JUL 2011. |
| Citações Web of Science: | 15 |
| Resumo | |
Trypanosoma cruzi is the causative agent of Chagas' disease, which affects some 8 - 10 million people in the Americas. The only two drugs approved for the etiological treatment of the disease in humans were launched more than 40 years ago and have serious drawbacks. In the present work, we revisit the unique characteristics of T. cruzi mitochondria and mitochondrial metabolism. The possibility of taking advantage of these peculiarities to target new drugs against this parasite is also discussed. (AU) | |
| Processo FAPESP: | 08/57596-4 - Metabolismo de aminoácidos de Trypanosoma cruzi: alvos putativos para terapia |
| Beneficiário: | Ariel Mariano Silber |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |